# C_2014356EN.01002201.xml

| 9.10.2014 | EN | Official Journal of the European Union | C 356/22 |
| --- | --- | --- | --- |

9.10.2014

EN

Official Journal of the European Union

C 356/22

---

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2012

2014/C 356/07

Subcommittee I on the free movement of goods

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2012, at their meeting on 15 July 2013:

| Annex I | List of new marketing authorisations |
| --- | --- |
| Annex II | List of renewed marketing authorisations |
| Annex III | List of extended marketing authorisations |
| Annex IV | List of withdrawn marketing authorisations |
| Annex V | List of suspended marketing authorisations |

Annex I

Annex I

List of new marketing authorisations

Annex II

Annex II

List of renewed marketing authorisations

Annex III

Annex III

List of extended marketing authorisations

Annex IV

Annex IV

List of withdrawn marketing authorisations

Annex V

Annex V

List of suspended marketing authorisations

---

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2012:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/11/711/001-030 | Matever | Norway | 1.6.2012 |
| EU/1/11/712/001-028 | Levetiracetam Accord | Norway | 13.4.2012 |
| EU/1/11/713/001-040 | Levetiracetam Actavis | Norway | 16.4.2012 |
| EU/1/11/715/001-002 | Plenadren | Iceland | 23.4.2012 |
| EU/1/11/721/001-021 | Paglitaz | Norway | 13.4.2012 |
| EU/1/11/721/001-021 | Paglitaz | Iceland | 17.4.2012 |
| EU/1/11/722/001-030 | Pioglitazone Accord | Norway | 11.4.2012 |
| EU/1/11/722/001-030 | Pioglitazon Accord | Liechtenstein | 30.4.2012 |
| EU/1/11/722/001-030 | Pioglitazone Accord | Iceland | 20.4.2012 |
| EU/1/11/723/001-021 | Pioglitazone Krka | Norway | 23.5.2012 |
| EU/1/11/723/001-021 | Pioglitazone Krka | Iceland | 20.4.2012 |
| EU/1/11/727/001 | Mercatopurine Nova lab. | Norway | 19.4.2012 |
| EU/1/11/727/001 | Mercaptopurine Nova Laboratories | Iceland | 3.4.2012 |
| EU/1/11/727/001 | Mercatopurine Nova Laboratories | Liechtenstein | 30.4.2012 |
| EU/1/11/729/001-006 | Onduarp | Norway | 8.5.2012 |
| EU/1/11/730/001-060 | Rasitrio | Iceland | 3.2.2012 |
| EU/1/11/738/001-003 | Levetiracetam Actavis Gr. | Norway | 1.3.2012 |
| EU/1/11/739/001-008 | Dasselta | Norway | 16.1.2012 |
| EU/1/11/740/001 | Ameluz | Iceland | 5.1.2012 |
| EU/1/11/740/001 | Ameluz | Norway | 16.1.2012 |
| EU/1/11/741/001 | Levetiracetam SUN | Norway | 27.1.2012 |
| EU/1/11/741/001 | Levetiracetam Sun | Iceland | 9.1.2012 |
| EU/1/11/742/001-010 | Efavirenz Teva | Norway | 13.2.2012 |
| EU/1/11/742/001-010 | Efavirenz Teva | Iceland | 24.1.2012 |
| EU/1/11/742/001-010 | Efavirenz Teva | Liechtenstein | 29.2.2012 |
| EU/1/11/743/001-015 | Repaglinide Accord | Norway | 13.2.2012 |
| EU/1/11/743/001-015 | Repaglinide Accord | Iceland | 19.1.2012 |
| EU/1/11/743/001-015 | Repaglinide Accord | Liechtenstein | 29.2.2012 |
| EU/1/11/744/001-002 | Topotecan Eagle | Iceland | 22.1.2012 |
| EU/1/11/744/001-002 | Topotecan Eagle | Liechtenstein | 29.2.2012 |
| EU/1/11/745/001-009 | Desloratadine Actavis | Iceland | 3.2.2012 |
| EU/1/11/745/001-009 | Desloratadine Actavis | Norway | 13.2.2012 |
| EU/1/11/746/001-012 | Desloratadine ratiopharm | Norway | 13.2.2012 |
| EU/1/11/746/001-012 | Desloratadine ratiopharm | Iceland | 3.2.2012 |
| EU/1/11/746/001-012 | Desloratadine ratiopharm | Liechtenstein | 29.2.2012 |
| EU/1/11/747/001 | Colobreathe | Iceland | 29.2.2012 |
| EU/1/11/747/001 | Colobreathe | Liechtenstein | 29.2.2012 |
| EU/1/11/748/001-006 | Docetaxel Mylan | Iceland | 7.2.2012 |
| EU/1/11/748/001-006 | Docetaxel Mylan | Liechtenstein | 29.2.2012 |
| EU/1/11/749/001-002 | Caprelsa | Liechtenstein | 30.4.2012 |
| EU/1/11/749/001-003 | Caprelsa | Iceland | 9.3.2012 |
| EU/1/11/749/001-002 | Caprelsa | Norway | 13.3.2012 |
| EU/1/12/750/001 | Esmya | Norway | 30.3.2012 |
| EU/1/12/750/001 | Esmya | Iceland | 14.3.2012 |
| EU/1/12/750/001 | Esmya | Liechtenstein | 30.4.2012 |
| EU/1/12/751/001 | Zelboraf | Norway | 14.3.2012 |
| EU/1/12/751/001 | Zelboraf | Iceland | 7.3.2012 |
| EU/1/12/751/001 | Zelboraf | Liechtenstein | 29.2.2012 |
| EU/1/12/752/001 | Vepacel | Norway | 1.3.2012 |
| EU/1/12/752/001 | Vepacel | Iceland | 9.3.2012 |
| EU/1/12/752/001 | Vepacel | Liechtenstein | 29.2.2012 |
| EU/1/12/753/001-012 | Signifor | Norway | 10.5.2012 |
| EU/1/12/753/001-012 | Signifor | Iceland | 24.5.2012 |
| EU/1/12/753/001-012 | Signifor | Liechtenstein | 30.6.2012 |
| EU/1/12/754/001-021 | Sepioglin | Norway | 10.4.2012 |
| EU/1/12/754/001-021 | Sepioglin | Iceland | 3.4.2012 |
| EU/1/12/754/001-021 | Sepioglin | Liechtenstein | 30.4.2012 |
| EU/1/12/755/001-027 | Pioglitazone Actavis | Norway | 13.4.2012 |
| EU/1/12/755/001-027 | Pioglitazone Actavis | Iceland | 30.4.2012 |
| EU/1/12/756/001-027 | Glidipion (ex Ogliton) | Norway | 13.4.2012 |
| EU/1/12/756/001-027 | Pioglitazone Actavis Group | Iceland | 13.4.2012 |
| EU/1/12/756/001-027 | Pioglitazone Actavis Group | Liechtenstein | 30.4.2012 |
| EU/1/12/757/001-030 | Pioglitazone Teva | Norway | 11.4.2012 |
| EU/1/12/757/001-030 | Pioglitazone Teva | Iceland | 23.4.2012 |
| EU/1/12/758/001-030 | Pioglitazone Teva Pharma | Norway | 17.4.2012 |
| EU/1/12/758/001-030 | Pioglitazone Teva Pharma | Iceland | 25.4.2012 |
| EU/1/12/759/001-003 | Zoledronic acid Actavis | Norway | 8.5.2012 |
| EU/1/12/759/001-003 | Zoledronic acid Actavis | Iceland | 16.5.2012 |
| EU/1/12/759/001-003 | Zoledronsäure Actavis | Liechtenstein | 30.4.2012 |
| EU/1/12/760/001-002 | Bronchitol | Norway | 18.5.2012 |
| EU/1/12/760/001-002 | Bronchitol | Iceland | 9.5.2012 |
| EU/1/12/761/001-002 | Capecitabine Teva | Norway | 30.5.2012 |
| EU/1/12/761/001-002 | Capecitabine Teva | Iceland | 20.5.2012 |
| EU/1/12/761/001-002 | Capecitabin Teva | Liechtenstein | 30.4.2012 |
| EU/1/12/762/001-018 | Capecitabine Accord | Iceland | 20.5.2012 |
| EU/1/12/762/001-018 | Capecitabin Accord | Liechtenstein | 30.4.2012 |
| EU/1/12/763/001-018 | Capecitabine Krka | Iceland | 16.5.2012 |
| EU/1/12/763/001-018 | Capecitabin Krka | Liechtenstein | 30.4.2012 |
| EU/1/12/763/001-018 | Capecitabine Krka | Norway | 14.6.2012 |
| EU/1/12/764/001 | Pixuvri | Norway | 14.6.2012 |
| EU/1/12/764/001 | Pixuvri | Iceland | 29.5.2012 |
| EU/1/12/764/001 | Pixuvri | Liechtenstein | 30.6.2012 |
| EU/1/12/765/001-004 | Sabervel | Iceland | 9.5.2012 |
| EU/1/12/765/001-006 | Sabervel | Norway | 8.5.2012 |
| EU/1/12/765/001-006 | Sabervel | Liechtenstein | 30.4.2012 |
| EU/1/12/766/001 | Sancuso | Norway | 10.5.2012 |
| EU/1/12/766/001 | Sancuso | Iceland | 20.5.2012 |
| EU/1/12/766/001 | Sancuso | Liechtenstein | 30.6.2012 |
| EU/1/12/767/001-007 | Nimenrix | Norway | 1.5.2012 |
| EU/1/12/767/001-007 | Nimenrix | Iceland | 16.5.2012 |
| EU/1/12/768/001 | Riluzole Zentiva | Iceland | 25.5.2012 |
| EU/1/12/768/001 | Riluzol Zentiva | Liechtenstein | 30.6.2012 |
| EU/1/12/769/001-003 | Docetaxel Accord | Iceland | 12.6.2012 |
| EU/1/12/769/001-003 | Docetaxel Accord | Liechtenstein | 30.6.2012 |
| EU/1/12/770/001-004 | Docetaxel Kabi | Norway | 19.6.2012 |
| EU/1/12/770/001-004 | Docetaxel Kabi | Iceland | 13.6.2012 |
| EU/1/12/770/001-004 | Docetaxel Kabi | Liechtenstein | 30.6.2012 |
| EU/2/11/134/001-014 | Inflacam | Norway | 6.1.2012 |
| EU/2/11/135/001-003 | Panacur AquaSol | Norway | 10.2.2012 |
| EU/2/11/136/001 | Truscient | Norway | 6.1.2012 |
| EU/2/11/136/001 | TruScient | Iceland | 12.1.2012 |
| EU/2/11/137/001-015 | Activyl Tick Plus | Norway | 13.2.2012 |
| EU/2/11/137/001-015 | Activyl Tick Plus | Iceland | 25.1.2012 |
| EU/2/11/137/001-015 | Activyl Tick Plus | Liechtenstein | 29.2.2012 |
| EU/2/12/138/001-003 | RevitaCAM | Iceland | 14.3.2012 |
| EU/2/12/139/001-003 | Zulvac 1 + 8 Bovis | Norway | 3.4.2012 |
| EU/2/12/139/001-003 | Zulvac 1 + 8 Bovis | Iceland | 4.4.2012 |
| EU/2/12/139/001-003 | Zulvac 1 + 8 Bovis | Liechtenstein | 30.4.2012 |

EU-Number

Product

Country

Date of authorisation

EU/1/11/711/001-030

Matever

Norway

1.6.2012

EU/1/11/712/001-028

Levetiracetam Accord

Norway

13.4.2012

EU/1/11/713/001-040

Levetiracetam Actavis

Norway

16.4.2012

EU/1/11/715/001-002

Plenadren

Iceland

23.4.2012

EU/1/11/721/001-021

Paglitaz

Norway

13.4.2012

EU/1/11/721/001-021

Paglitaz

Iceland

17.4.2012

EU/1/11/722/001-030

Pioglitazone Accord

Norway

11.4.2012

EU/1/11/722/001-030

Pioglitazon Accord

Liechtenstein

30.4.2012

EU/1/11/722/001-030

Pioglitazone Accord

Iceland

20.4.2012

EU/1/11/723/001-021

Pioglitazone Krka

Norway

23.5.2012

EU/1/11/723/001-021

Pioglitazone Krka

Iceland

20.4.2012

EU/1/11/727/001

Mercatopurine Nova lab.

Norway

19.4.2012

EU/1/11/727/001

Mercaptopurine Nova Laboratories

Iceland

3.4.2012

EU/1/11/727/001

Mercatopurine Nova Laboratories

Liechtenstein

30.4.2012

EU/1/11/729/001-006

Onduarp

Norway

8.5.2012

EU/1/11/730/001-060

Rasitrio

Iceland

3.2.2012

EU/1/11/738/001-003

Levetiracetam Actavis Gr.

Norway

1.3.2012

EU/1/11/739/001-008

Dasselta

Norway

16.1.2012

EU/1/11/740/001

Ameluz

Iceland

5.1.2012

EU/1/11/740/001

Ameluz

Norway

16.1.2012

EU/1/11/741/001

Levetiracetam SUN

Norway

27.1.2012

EU/1/11/741/001

Levetiracetam Sun

Iceland

9.1.2012

EU/1/11/742/001-010

Efavirenz Teva

Norway

13.2.2012

EU/1/11/742/001-010

Efavirenz Teva

Iceland

24.1.2012

EU/1/11/742/001-010

Efavirenz Teva

Liechtenstein

29.2.2012

EU/1/11/743/001-015

Repaglinide Accord

Norway

13.2.2012

EU/1/11/743/001-015

Repaglinide Accord

Iceland

19.1.2012

EU/1/11/743/001-015

Repaglinide Accord

Liechtenstein

29.2.2012

EU/1/11/744/001-002

Topotecan Eagle

Iceland

22.1.2012

EU/1/11/744/001-002

Topotecan Eagle

Liechtenstein

29.2.2012

EU/1/11/745/001-009

Desloratadine Actavis

Iceland

3.2.2012

EU/1/11/745/001-009

Desloratadine Actavis

Norway

13.2.2012

EU/1/11/746/001-012

Desloratadine ratiopharm

Norway

13.2.2012

EU/1/11/746/001-012

Desloratadine ratiopharm

Iceland

3.2.2012

EU/1/11/746/001-012

Desloratadine ratiopharm

Liechtenstein

29.2.2012

EU/1/11/747/001

Colobreathe

Iceland

29.2.2012

EU/1/11/747/001

Colobreathe

Liechtenstein

29.2.2012

EU/1/11/748/001-006

Docetaxel Mylan

Iceland

7.2.2012

EU/1/11/748/001-006

Docetaxel Mylan

Liechtenstein

29.2.2012

EU/1/11/749/001-002

Caprelsa

Liechtenstein

30.4.2012

EU/1/11/749/001-003

Caprelsa

Iceland

9.3.2012

EU/1/11/749/001-002

Caprelsa

Norway

13.3.2012

EU/1/12/750/001

Esmya

Norway

30.3.2012

EU/1/12/750/001

Esmya

Iceland

14.3.2012

EU/1/12/750/001

Esmya

Liechtenstein

30.4.2012

EU/1/12/751/001

Zelboraf

Norway

14.3.2012

EU/1/12/751/001

Zelboraf

Iceland

7.3.2012

EU/1/12/751/001

Zelboraf

Liechtenstein

29.2.2012

EU/1/12/752/001

Vepacel

Norway

1.3.2012

EU/1/12/752/001

Vepacel

Iceland

9.3.2012

EU/1/12/752/001

Vepacel

Liechtenstein

29.2.2012

EU/1/12/753/001-012

Signifor

Norway

10.5.2012

EU/1/12/753/001-012

Signifor

Iceland

24.5.2012

EU/1/12/753/001-012

Signifor

Liechtenstein

30.6.2012

EU/1/12/754/001-021

Sepioglin

Norway

10.4.2012

EU/1/12/754/001-021

Sepioglin

Iceland

3.4.2012

EU/1/12/754/001-021

Sepioglin

Liechtenstein

30.4.2012

EU/1/12/755/001-027

Pioglitazone Actavis

Norway

13.4.2012

EU/1/12/755/001-027

Pioglitazone Actavis

Iceland

30.4.2012

EU/1/12/756/001-027

Glidipion (ex Ogliton)

Norway

13.4.2012

EU/1/12/756/001-027

Pioglitazone Actavis Group

Iceland

13.4.2012

EU/1/12/756/001-027

Pioglitazone Actavis Group

Liechtenstein

30.4.2012

EU/1/12/757/001-030

Pioglitazone Teva

Norway

11.4.2012

EU/1/12/757/001-030

Pioglitazone Teva

Iceland

23.4.2012

EU/1/12/758/001-030

Pioglitazone Teva Pharma

Norway

17.4.2012

EU/1/12/758/001-030

Pioglitazone Teva Pharma

Iceland

25.4.2012

EU/1/12/759/001-003

Zoledronic acid Actavis

Norway

8.5.2012

EU/1/12/759/001-003

Zoledronic acid Actavis

Iceland

16.5.2012

EU/1/12/759/001-003

Zoledronsäure Actavis

Liechtenstein

30.4.2012

EU/1/12/760/001-002

Bronchitol

Norway

18.5.2012

EU/1/12/760/001-002

Bronchitol

Iceland

9.5.2012

EU/1/12/761/001-002

Capecitabine Teva

Norway

30.5.2012

EU/1/12/761/001-002

Capecitabine Teva

Iceland

20.5.2012

EU/1/12/761/001-002

Capecitabin Teva

Liechtenstein

30.4.2012

EU/1/12/762/001-018

Capecitabine Accord

Iceland

20.5.2012

EU/1/12/762/001-018

Capecitabin Accord

Liechtenstein

30.4.2012

EU/1/12/763/001-018

Capecitabine Krka

Iceland

16.5.2012

EU/1/12/763/001-018

Capecitabin Krka

Liechtenstein

30.4.2012

EU/1/12/763/001-018

Capecitabine Krka

Norway

14.6.2012

EU/1/12/764/001

Pixuvri

Norway

14.6.2012

EU/1/12/764/001

Pixuvri

Iceland

29.5.2012

EU/1/12/764/001

Pixuvri

Liechtenstein

30.6.2012

EU/1/12/765/001-004

Sabervel

Iceland

9.5.2012

EU/1/12/765/001-006

Sabervel

Norway

8.5.2012

EU/1/12/765/001-006

Sabervel

Liechtenstein

30.4.2012

EU/1/12/766/001

Sancuso

Norway

10.5.2012

EU/1/12/766/001

Sancuso

Iceland

20.5.2012

EU/1/12/766/001

Sancuso

Liechtenstein

30.6.2012

EU/1/12/767/001-007

Nimenrix

Norway

1.5.2012

EU/1/12/767/001-007

Nimenrix

Iceland

16.5.2012

EU/1/12/768/001

Riluzole Zentiva

Iceland

25.5.2012

EU/1/12/768/001

Riluzol Zentiva

Liechtenstein

30.6.2012

EU/1/12/769/001-003

Docetaxel Accord

Iceland

12.6.2012

EU/1/12/769/001-003

Docetaxel Accord

Liechtenstein

30.6.2012

EU/1/12/770/001-004

Docetaxel Kabi

Norway

19.6.2012

EU/1/12/770/001-004

Docetaxel Kabi

Iceland

13.6.2012

EU/1/12/770/001-004

Docetaxel Kabi

Liechtenstein

30.6.2012

EU/2/11/134/001-014

Inflacam

Norway

6.1.2012

EU/2/11/135/001-003

Panacur AquaSol

Norway

10.2.2012

EU/2/11/136/001

Truscient

Norway

6.1.2012

EU/2/11/136/001

TruScient

Iceland

12.1.2012

EU/2/11/137/001-015

Activyl Tick Plus

Norway

13.2.2012

EU/2/11/137/001-015

Activyl Tick Plus

Iceland

25.1.2012

EU/2/11/137/001-015

Activyl Tick Plus

Liechtenstein

29.2.2012

EU/2/12/138/001-003

RevitaCAM

Iceland

14.3.2012

EU/2/12/139/001-003

Zulvac 1 + 8 Bovis

Norway

3.4.2012

EU/2/12/139/001-003

Zulvac 1 + 8 Bovis

Iceland

4.4.2012

EU/2/12/139/001-003

Zulvac 1 + 8 Bovis

Liechtenstein

30.4.2012

---

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2012:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/01/197/001-005 | Foscan | Iceland | 14.5.2012 |
| EU/1/01/200/001-002 | Viread | Norway | 6.1.2012 |
| EU/1/01/200/001-002 | Viread | Iceland | 5.1.2012 |
| EU/1/02/209/001-008 | Dynastat | Norway | 8.3.2012 |
| EU/1/02/209/001-008 | Dynastat | Iceland | 7.2.2012 |
| EU/1/02/209/001-008 | Dynastat | Liechtenstein | 29.2.2012 |
| EU/1/02/212/001-026 | Vfend | Norway | 6.3.2012 |
| EU/1/02/212/001-026 | Vfend | Iceland | 14.3.2012 |
| EU/1/02/212/001-026 | Vfend | Liechtenstein | 30.4.2012 |
| EU/1/02/216/001-002 | Invanz | Norway | 19.1.2012 |
| EU/1/02/216/001-002 | Invanz | Iceland | 20.1.2012 |
| EU/1/02/216/001-002 | Invanz | Liechtenstein | 29.2.2012 |
| EU/1/02/220/001-006 | Tracleer | Norway | 8.5.2012 |
| EU/1/02/220/001-006 | Tracleer | Iceland | 20.5.2012 |
| EU/1/02/220/001-006 | Tracleer | Liechtenstein | 30.4.2012 |
| EU/1/02/222/001-005 | Tamiflu | Norway | 8.3.2012 |
| EU/1/02/222/001-005 | Tamiflu | Iceland | 19.6.2012 |
| EU/1/02/222/001-005 | Tamiflu | Liechtenstein | 30.6.2012 |
| EU/1/06/334/001-005 | Evoltra | Liechtenstein | 30.4.2012 |
| EU/1/06/347/001-008 | Sutent | Liechtenstein | 29.2.2012 |
| EU/1/06/366/005-022 | Tandemact | Norway | 11.4.2012 |
| EU/1/06/366/005-022 | Tandemact | Iceland | 22.3.2012 |
| EU/1/06/366/005-022 | Tandemact | Liechtenstein | 30.4.2012 |
| EU/1/06/367/001-012 | Diacomit | Norway | 6.3.2012 |
| EU/1/06/367/001-012 | Diacomit | Iceland | 7.2.2012 |
| EU/1/06/367/001-012 | Diacomit | Liechtenstein | 29.2.2012 |
| EU/1/06/370/001-039 | Exforge | Norway | 16.1.2012 |
| EU/1/06/370/001-039 | EXFORGE | Iceland | 3.2.2012 |
| EU/1/06/371/001-039 | Dafiro | Iceland | 8.2.2012 |
| EU/1/06/371/001-039 | Dafiro | Liechtenstein | 29.2.2012 |
| EU/1/06/372/001-039 | Copalia | Norway | 11.1.2012 |
| EU/1/06/373/001-039 | Imprida | Norway | 16.1.2012 |
| EU/1/06/373/001-039 | Imprida | Iceland | 6.2.2012 |
| EU/1/06/374/001 | Lucentis | Norway | 17.1.2012 |
| EU/1/06/374/001 | Lucentis | Iceland | 12.1.2012 |
| EU/1/06/376/001-033 | Irbesartan Zentiva (ex-Winthrop) | Norway | 14.2.2012 |
| EU/1/06/376/001-033 | Irbesartan Zentiva | Iceland | 7.2.2012 |
| EU/1/06/376/001-033 | Irbesartan Winthrop | Liechtenstein | 29.2.2012 |
| EU/1/06/377/001-028 | Irbesartan HCT Zentiva (ex-Winthrop) | Norway | 16.4.2012 |
| EU/1/06/377/001-028 | Irbesartan HCT Zentiva | Iceland | 22.3.2012 |
| EU/1/06/377/001-028 | Irbesartan HCT | Liechtenstein | 30.4.2012 |
| EU/1/06/378/001-017 | Inovelon | Norway | 6.3.2012 |
| EU/1/06/378/001-017 | Inovelon | Iceland | 24.1.2012 |
| EU/1/06/378/001-017 | Inovelon | Liechtenstein | 29.2.2012 |
| EU/1/06/379/001 | Cystadane | Iceland | 9.3.2012 |
| EU/1/06/379/001 | Cystadane | Liechtenstein | 29.2.2012 |
| EU/1/06/386/001-015, 020-024, 029-033, 038-042, 047-051, 056-057, 088102, 113-150, 163-168 | Insulin Human Winthrop | Norway | 6.1.2012 |
| EU/1/07/382/001-018 | Xelevia | Norway | 14.2.2012 |
| EU/1/07/382/001-018 | Xelevia | Iceland | 6.2.2012 |
| EU/1/07/382/001-018 | Xelevia | Liechtenstein | 29.2.2012 |
| EU/1/07/383/001-018 | Januvia | Norway | 26.3.2012 |
| EU/1/07/383/001-018 | Januvia | Iceland | 11.5.2012 |
| EU/1/07/383/001-018 | Januvia | Liechtenstein | 30.4.2012 |
| EU/1/07/384/003-005 | Docetaxel Winthrop | Norway | 10.4.2012 |
| EU/1/07/384/003-005 | Docetaxel Winthrop | Iceland | 23.3.2012 |
| EU/1/07/384/003-005 | Docetaxel Winthrop | Liechtenstein | 30.4.2012 |
| EU/1/07/386/001-018 | Toviaz | Norway | 11.4.2012 |
| EU/1/07/386/001-018 | Toviaz | Iceland | 10.4.2012 |
| EU/1/07/386/001-018 | Toviaz | Liechtenstein | 30.4.2012 |
| EU/1/07/387/001-026 | Advagraf | Norway | 2.5.2012 |
| EU/1/07/387/001-026 | Advagraf | Iceland | 9.5.2012 |
| EU/1/07/387/001-026 | Advagraf | Liechtenstein | 30.4.2012 |
| EU/1/07/388/001-003 | Sebivo | Norway | 8.5.2012 |
| EU/1/07/388/001-003 | Sebivo | Iceland | 16.5.2012 |
| EU/1/07/388/001-003 | Sebivo | Liechtenstein | 30.4.2012 |
| EU/1/07/389/001-003 | Orencia | Norway | 10.4.2012 |
| EU/1/07/389/001-003 | Orencia | Iceland | 10.4.2012 |
| EU/1/07/389/001-003 | Orencia | Liechtenstein | 30.4.2012 |
| EU/1/07/390/001-004 | Altargo | Norway | 8.5.2012 |
| EU/1/07/390/001-004 | Altargo | Iceland | 16.5.2012 |
| EU/1/07/390/001-004 | Altargo | Liechtenstein | 30.4.2012 |
| EU/1/07/391/001-004 | Revlimid | Norway | 3.5.2012 |
| EU/1/07/391/001-004 | Revlimid | Iceland | 9.5.2012 |
| EU/1/07/391/001-004 | Revlimid | Liechtenstein | 30.4.2012 |
| EU/1/07/392/001-003 | Circadin | Norway | 16.5.2012 |
| EU/1/07/392/001-003 | Circadin | Iceland | 10.5.2012 |
| EU/1/07/392/001-003 | Circadin | Liechtenstein | 30.6.2012 |
| EU/1/07/394/001-009 | Optaflu | Norway | 20.6.2012 |
| EU/1/07/395/001-095 | Invega | Liechtenstein | 30.6.2012 |
| EU/1/07/396/001-003 | Pergoveris | Iceland | 20.6.2012 |
| EU/1/07/396/001-003 | Pergoveris | Liechtenstein | 30.6.2012 |
| EU/1/07/398/001-014 | Optimark | Norway | 27.6.2012 |
| EU/1/07/399/001-006 | Aerinaze | Norway | 18.6.2012 |
| EU/1/07/399/001-006 | Aerinaze | Liechtenstein | 30.6.2012 |
| EU/1/07/399/001-006 | Aerinaze | Iceland | 20.6.2012 |
| EU/1/07/400/008-013, 017-024 | Mircera | Iceland | 7.6.2012 |
| EU/1/07/400/008-013, 017-024 | Mircera | Norway | 14.6.2012 |
| EU/1/07/400/017-024 | Mircera | Liechtenstein | 30.6.2012 |
| EU/1/07/401/007-016 | alli | Norway | 29.6.2012 |
| EU/1/07/412/001-052 | Abseamed | Liechtenstein | 30.6.2012 |
| EU/1/07/423/001-003 | Vectibix | Norway | 19.3.2012 |
| EU/1/07/423/001-003 | Vectibix | Iceland | 9.3.2012 |
| EU/1/07/440/001-003 | Tyverb | Liechtenstein | 30.4.2012 |
| EU/1/07/440/001-006 | Tyverb | Norway | 2.5.2012 |
| EU/1/07/440/001-006 | Tyverb | Iceland | 11.5.2012 |
| EU/1/10/625/001&003 | Arzerra | Iceland | 17.2.2012 |
| EU/1/10/625/001&003 | Arzerra | Norway | 18.5.2012 |
| EU/1/10/628/001-004 | Votrient | Norway | 19.6.2012 |
| EU/1/10/628/001-004 | Votrient | Iceland | 13.6.2012 |
| EU/1/11/699/001-004 | Fampyra | Norway | 19.6.2012 |
| EU/1/11/699/001-004 | Fampyra | Iceland | 13.6.2012 |
| EU/1/11/699/001-004 | Fampyra | Liechtenstein | 30.6.2012 |
| EU/2/05/053/001-003 | Naxcel | Norway | 14.2.2012 |
| EU/2/06/068/001-004 | Ypozane | Norway | 13.2.2012 |
| EU/2/06/068/001-004 | Ypozane | Iceland | 18.1.2012 |
| EU/2/06/068/001-004 | Ypozane | Liechtenstein | 30.4.2012 |
| EU/2/06/070/001-008 | Meloxidyl | Iceland | 13.1.2012 |
| EU/2/07/071/001-003 | SLENTROL | Iceland | 7.5.2012 |
| EU/2/07/071/001-003 | Slentrol | Liechtenstein | 30.4.2012 |
| EU/2/07/072/001-004 | Suprelorin | Iceland | 21.6.2012 |
| EU/2/07/074/001-006 | Prilactone | Iceland | 13.6.2012 |
| EU/2/07/075/001-004 | Circovac | Liechtenstein | 30.6.2012 |
| EU/2/07/075/001-004 | Circovac | Iceland | 4.6.2012 |

EU-Number

Product

Country

Date of authorisation

EU/1/01/197/001-005

Foscan

Iceland

14.5.2012

EU/1/01/200/001-002

Viread

Norway

6.1.2012

EU/1/01/200/001-002

Viread

Iceland

5.1.2012

EU/1/02/209/001-008

Dynastat

Norway

8.3.2012

EU/1/02/209/001-008

Dynastat

Iceland

7.2.2012

EU/1/02/209/001-008

Dynastat

Liechtenstein

29.2.2012

EU/1/02/212/001-026

Vfend

Norway

6.3.2012

EU/1/02/212/001-026

Vfend

Iceland

14.3.2012

EU/1/02/212/001-026

Vfend

Liechtenstein

30.4.2012

EU/1/02/216/001-002

Invanz

Norway

19.1.2012

EU/1/02/216/001-002

Invanz

Iceland

20.1.2012

EU/1/02/216/001-002

Invanz

Liechtenstein

29.2.2012

EU/1/02/220/001-006

Tracleer

Norway

8.5.2012

EU/1/02/220/001-006

Tracleer

Iceland

20.5.2012

EU/1/02/220/001-006

Tracleer

Liechtenstein

30.4.2012

EU/1/02/222/001-005

Tamiflu

Norway

8.3.2012

EU/1/02/222/001-005

Tamiflu

Iceland

19.6.2012

EU/1/02/222/001-005

Tamiflu

Liechtenstein

30.6.2012

EU/1/06/334/001-005

Evoltra

Liechtenstein

30.4.2012

EU/1/06/347/001-008

Sutent

Liechtenstein

29.2.2012

EU/1/06/366/005-022

Tandemact

Norway

11.4.2012

EU/1/06/366/005-022

Tandemact

Iceland

22.3.2012

EU/1/06/366/005-022

Tandemact

Liechtenstein

30.4.2012

EU/1/06/367/001-012

Diacomit

Norway

6.3.2012

EU/1/06/367/001-012

Diacomit

Iceland

7.2.2012

EU/1/06/367/001-012

Diacomit

Liechtenstein

29.2.2012

EU/1/06/370/001-039

Exforge

Norway

16.1.2012

EU/1/06/370/001-039

EXFORGE

Iceland

3.2.2012

EU/1/06/371/001-039

Dafiro

Iceland

8.2.2012

EU/1/06/371/001-039

Dafiro

Liechtenstein

29.2.2012

EU/1/06/372/001-039

Copalia

Norway

11.1.2012

EU/1/06/373/001-039

Imprida

Norway

16.1.2012

EU/1/06/373/001-039

Imprida

Iceland

6.2.2012

EU/1/06/374/001

Lucentis

Norway

17.1.2012

EU/1/06/374/001

Lucentis

Iceland

12.1.2012

EU/1/06/376/001-033

Irbesartan Zentiva (ex-Winthrop)

Norway

14.2.2012

EU/1/06/376/001-033

Irbesartan Zentiva

Iceland

7.2.2012

EU/1/06/376/001-033

Irbesartan Winthrop

Liechtenstein

29.2.2012

EU/1/06/377/001-028

Irbesartan HCT Zentiva (ex-Winthrop)

Norway

16.4.2012

EU/1/06/377/001-028

Irbesartan HCT Zentiva

Iceland

22.3.2012

EU/1/06/377/001-028

Irbesartan HCT

Liechtenstein

30.4.2012

EU/1/06/378/001-017

Inovelon

Norway

6.3.2012

EU/1/06/378/001-017

Inovelon

Iceland

24.1.2012

EU/1/06/378/001-017

Inovelon

Liechtenstein

29.2.2012

EU/1/06/379/001

Cystadane

Iceland

9.3.2012

EU/1/06/379/001

Cystadane

Liechtenstein

29.2.2012

EU/1/06/386/001-015, 020-024, 029-033, 038-042, 047-051, 056-057, 088102, 113-150, 163-168

Insulin Human Winthrop

Norway

6.1.2012

EU/1/07/382/001-018

Xelevia

Norway

14.2.2012

EU/1/07/382/001-018

Xelevia

Iceland

6.2.2012

EU/1/07/382/001-018

Xelevia

Liechtenstein

29.2.2012

EU/1/07/383/001-018

Januvia

Norway

26.3.2012

EU/1/07/383/001-018

Januvia

Iceland

11.5.2012

EU/1/07/383/001-018

Januvia

Liechtenstein

30.4.2012

EU/1/07/384/003-005

Docetaxel Winthrop

Norway

10.4.2012

EU/1/07/384/003-005

Docetaxel Winthrop

Iceland

23.3.2012

EU/1/07/384/003-005

Docetaxel Winthrop

Liechtenstein

30.4.2012

EU/1/07/386/001-018

Toviaz

Norway

11.4.2012

EU/1/07/386/001-018

Toviaz

Iceland

10.4.2012

EU/1/07/386/001-018

Toviaz

Liechtenstein

30.4.2012

EU/1/07/387/001-026

Advagraf

Norway

2.5.2012

EU/1/07/387/001-026

Advagraf

Iceland

9.5.2012

EU/1/07/387/001-026

Advagraf

Liechtenstein

30.4.2012

EU/1/07/388/001-003

Sebivo

Norway

8.5.2012

EU/1/07/388/001-003

Sebivo

Iceland

16.5.2012

EU/1/07/388/001-003

Sebivo

Liechtenstein

30.4.2012

EU/1/07/389/001-003

Orencia

Norway

10.4.2012

EU/1/07/389/001-003

Orencia

Iceland

10.4.2012

EU/1/07/389/001-003

Orencia

Liechtenstein

30.4.2012

EU/1/07/390/001-004

Altargo

Norway

8.5.2012

EU/1/07/390/001-004

Altargo

Iceland

16.5.2012

EU/1/07/390/001-004

Altargo

Liechtenstein

30.4.2012

EU/1/07/391/001-004

Revlimid

Norway

3.5.2012

EU/1/07/391/001-004

Revlimid

Iceland

9.5.2012

EU/1/07/391/001-004

Revlimid

Liechtenstein

30.4.2012

EU/1/07/392/001-003

Circadin

Norway

16.5.2012

EU/1/07/392/001-003

Circadin

Iceland

10.5.2012

EU/1/07/392/001-003

Circadin

Liechtenstein

30.6.2012

EU/1/07/394/001-009

Optaflu

Norway

20.6.2012

EU/1/07/395/001-095

Invega

Liechtenstein

30.6.2012

EU/1/07/396/001-003

Pergoveris

Iceland

20.6.2012

EU/1/07/396/001-003

Pergoveris

Liechtenstein

30.6.2012

EU/1/07/398/001-014

Optimark

Norway

27.6.2012

EU/1/07/399/001-006

Aerinaze

Norway

18.6.2012

EU/1/07/399/001-006

Aerinaze

Liechtenstein

30.6.2012

EU/1/07/399/001-006

Aerinaze

Iceland

20.6.2012

EU/1/07/400/008-013, 017-024

Mircera

Iceland

7.6.2012

EU/1/07/400/008-013, 017-024

Mircera

Norway

14.6.2012

EU/1/07/400/017-024

Mircera

Liechtenstein

30.6.2012

EU/1/07/401/007-016

alli

Norway

29.6.2012

EU/1/07/412/001-052

Abseamed

Liechtenstein

30.6.2012

EU/1/07/423/001-003

Vectibix

Norway

19.3.2012

EU/1/07/423/001-003

Vectibix

Iceland

9.3.2012

EU/1/07/440/001-003

Tyverb

Liechtenstein

30.4.2012

EU/1/07/440/001-006

Tyverb

Norway

2.5.2012

EU/1/07/440/001-006

Tyverb

Iceland

11.5.2012

EU/1/10/625/001&003

Arzerra

Iceland

17.2.2012

EU/1/10/625/001&003

Arzerra

Norway

18.5.2012

EU/1/10/628/001-004

Votrient

Norway

19.6.2012

EU/1/10/628/001-004

Votrient

Iceland

13.6.2012

EU/1/11/699/001-004

Fampyra

Norway

19.6.2012

EU/1/11/699/001-004

Fampyra

Iceland

13.6.2012

EU/1/11/699/001-004

Fampyra

Liechtenstein

30.6.2012

EU/2/05/053/001-003

Naxcel

Norway

14.2.2012

EU/2/06/068/001-004

Ypozane

Norway

13.2.2012

EU/2/06/068/001-004

Ypozane

Iceland

18.1.2012

EU/2/06/068/001-004

Ypozane

Liechtenstein

30.4.2012

EU/2/06/070/001-008

Meloxidyl

Iceland

13.1.2012

EU/2/07/071/001-003

SLENTROL

Iceland

7.5.2012

EU/2/07/071/001-003

Slentrol

Liechtenstein

30.4.2012

EU/2/07/072/001-004

Suprelorin

Iceland

21.6.2012

EU/2/07/074/001-006

Prilactone

Iceland

13.6.2012

EU/2/07/075/001-004

Circovac

Liechtenstein

30.6.2012

EU/2/07/075/001-004

Circovac

Iceland

4.6.2012

---

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2012:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/141/002 | Myocet | Liechtenstein | 30.4.2012 |
| EU/1/02/222/05 | Tamiflu | Iceland | 6.2.2012 |
| EU/1/03/262/009-010 | Emend | Norway | 5.1.2012 |
| EU/1/03/262/009-010 | Emend | Iceland | 3.2.2012 |
| EU/1/03/271/007-010 | Advate | Norway | 23.1.2012 |
| EU/1/03/271/007-010 | Advate | Iceland | 17.1.2012 |
| EU/1/05/318/003 | Revatio | Norway | 13.4.2012 |
| EU/1/05/318/003 | Revatio | Iceland | 17.4.2012 |
| EU/1/05/318/003 | Revatio | Liechtenstein | 30.4.2012 |
| EU/1/06/339/003 | Preotact | Liechtenstein | 30.6.2012 |
| EU/1/08/465/021 | Clopidogrel Zentiva | Liechtenstein | 30.6.2012 |
| EU/1/08/468/002 | INTELENCE | Iceland | 3.1.2012 |
| EU/1/08/470/018-019 | Vimpat | Norway | 14.3.2012 |
| EU/1/08/470/018-019 | Vimpat | Iceland | 14.3.2012 |
| EU/1/08/470/018-019 | Vimpat | Liechtenstein | 30.4.2012 |
| EU/1/08/472/011-021 | Xarelto | Norway | 4.1.2012 |
| EU/1/08/475/035-060 | Olanzapin Mylan | Liechtenstein | 29.2.2012 |
| EU/1/09/536/003-004 | Topotecan Actavis | Liechtenstein | 30.4.2012 |
| EU/1/09/551/013-027 | Vizarsin | Iceland | 7.6.2012 |
| EU/1/09/551/013-027 | Vizarsin | Liechtenstein | 30.6.2012 |
| EU/1/09/571/002 | Pandemic influenza vaccine H5N1 Baxter | Liechtenstein | 30.4.2012 |
| EU/1/11/667/004 | Esbriet | Liechtenstein | 30.4.2012 |
| EU/1/11/699/003-004 | Fampyra | Liechtenstein | 30.4.2012 |
| EU/1/11/701/029-032 | Levetiracetam Teva | Liechtenstein | 30.6.2012 |
| EU/1/11/703/003 | Xgeva | Liechtenstein | 29.2.2012 |
| EU/1/11/704/002 | Victrelis | Liechtenstein | 30.4.2012 |
| EU/1/11/720/002 | Incivo | Liechtenstein | 30.6.2012 |
| EU/1/97/044/009 | Tasmar | Liechtenstein | 30.4.2012 |
| EU/2/07/078/015-017 | Rheumocam | Norway | 13.2.2012 |
| EU/2/07/078/015-017 | Rheumocam | Iceland | 7.2.2012 |
| EU/2/07/078/015-017 | Rheumocam | Liechtenstein | 29.2.2012 |
| EU/2/08/085/002-006 | Easotic | Liechtenstein | 30.4.2012 |
| EU/2/08/090/027 | Loxicom | Liechtenstein | 30.6.2012 |
| EU/2/10/114/003 | Hiprabovis IBR Marker Live | Liechtenstein | 29.2.2012 |
| EU/2/97/004/049 | Metacam | Liechtenstein | 29.2.2012 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/141/002

Myocet

Liechtenstein

30.4.2012

EU/1/02/222/05

Tamiflu

Iceland

6.2.2012

EU/1/03/262/009-010

Emend

Norway

5.1.2012

EU/1/03/262/009-010

Emend

Iceland

3.2.2012

EU/1/03/271/007-010

Advate

Norway

23.1.2012

EU/1/03/271/007-010

Advate

Iceland

17.1.2012

EU/1/05/318/003

Revatio

Norway

13.4.2012

EU/1/05/318/003

Revatio

Iceland

17.4.2012

EU/1/05/318/003

Revatio

Liechtenstein

30.4.2012

EU/1/06/339/003

Preotact

Liechtenstein

30.6.2012

EU/1/08/465/021

Clopidogrel Zentiva

Liechtenstein

30.6.2012

EU/1/08/468/002

INTELENCE

Iceland

3.1.2012

EU/1/08/470/018-019

Vimpat

Norway

14.3.2012

EU/1/08/470/018-019

Vimpat

Iceland

14.3.2012

EU/1/08/470/018-019

Vimpat

Liechtenstein

30.4.2012

EU/1/08/472/011-021

Xarelto

Norway

4.1.2012

EU/1/08/475/035-060

Olanzapin Mylan

Liechtenstein

29.2.2012

EU/1/09/536/003-004

Topotecan Actavis

Liechtenstein

30.4.2012

EU/1/09/551/013-027

Vizarsin

Iceland

7.6.2012

EU/1/09/551/013-027

Vizarsin

Liechtenstein

30.6.2012

EU/1/09/571/002

Pandemic influenza vaccine H5N1 Baxter

Liechtenstein

30.4.2012

EU/1/11/667/004

Esbriet

Liechtenstein

30.4.2012

EU/1/11/699/003-004

Fampyra

Liechtenstein

30.4.2012

EU/1/11/701/029-032

Levetiracetam Teva

Liechtenstein

30.6.2012

EU/1/11/703/003

Xgeva

Liechtenstein

29.2.2012

EU/1/11/704/002

Victrelis

Liechtenstein

30.4.2012

EU/1/11/720/002

Incivo

Liechtenstein

30.6.2012

EU/1/97/044/009

Tasmar

Liechtenstein

30.4.2012

EU/2/07/078/015-017

Rheumocam

Norway

13.2.2012

EU/2/07/078/015-017

Rheumocam

Iceland

7.2.2012

EU/2/07/078/015-017

Rheumocam

Liechtenstein

29.2.2012

EU/2/08/085/002-006

Easotic

Liechtenstein

30.4.2012

EU/2/08/090/027

Loxicom

Liechtenstein

30.6.2012

EU/2/10/114/003

Hiprabovis IBR Marker Live

Liechtenstein

29.2.2012

EU/2/97/004/049

Metacam

Liechtenstein

29.2.2012

---

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2012:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/02/255/001-002 | Xigris | Iceland | 25.6.2012 |
| EU/1/04/272/001-002 | PhotoBarr | Norway | 24.5.2012 |
| EU/1/04/272/001-002 | Photobarr | Iceland | 20.5.2012 |
| EU/1/04/272/001-002 | PhotoBarr | Liechtenstein | 30.6.2012 |
| EU/1/06/335/001 | Valtropin | Iceland | 5.6.2012 |
| EU/1/06/335/001 | Valtropin | Liechtenstein | 30.6.2012 |
| EU/1/06/351/001-003 | Livensa | Iceland | 11.4.2012 |
| EU/1/06/351/001-003 | Livensa | Liechtenstein | 30.4.2012 |
| EU/1/06/352/001-003 | Intrinsa | Liechtenstein | 30.6.2012 |
| EU/1/06/352/001-003 | Intrinsa | Iceland | 23.6.2012 |
| EU/1/09/534/001-007 | Clopidogrel Hexal | Iceland | 2.3.2012 |
| EU/1/09/534/001-007 | Clopidgrel Hexal | Liechtenstein | 29.2.2012 |
| EU/1/09/548/001-007 | Clopidogrel Acino Pharma GmbH | Iceland | 2.3.2012 |
| EU/1/09/548/001-007 | Clopidgrel Acino Pharma GmbH | Liechtenstein | 29.2.2012 |
| EU/1/09/549/001-007 | Clopidogrel Acino Pharma | Iceland | 2.3.2012 |
| EU/1/09/549/001-007 | Clopidogrel Acino Pharma | Liechtenstein | 29.2.2012 |
| EU/1/10/630/001-002 | Docefrez | Iceland | 20.6.2012 |
| EU/1/10/630/001-002 | Docefrez | Liechtenstein | 30.6.2012 |
| EU/1/97/035/003-004 | Refludan | Iceland | 24.5.2012 |
| EU/1/97/035/001-004 | Refludan | Norway | 6.6.2012 |
| EU/1/97/035/001-004 | Refludan | Liechtenstein | 30.6.2012 |
| EU/2/00/028/002-008 | Zubrin | Iceland | 17.4.2012 |
| EU/2/00/028/002-008 | Zubrin | Liechtenstein | 30.4.2012 |
| EU/2/03/040/001-002 | Gonazon | Norway | 2.4.2012 |
| EU/2/03/040/001-002 | Gonazon | Iceland | 17.4.2012 |
| EU/2/03/040/001-002 | Gonazon | Liechtenstein | 30.4.2012 |
| EU/2/06/060/001-002 | Poulvac FluFend H5N3 RG | Liechtenstein | 30.6.2012 |

EU-Number

Product

Country

Date of authorisation

EU/1/02/255/001-002

Xigris

Iceland

25.6.2012

EU/1/04/272/001-002

PhotoBarr

Norway

24.5.2012

EU/1/04/272/001-002

Photobarr

Iceland

20.5.2012

EU/1/04/272/001-002

PhotoBarr

Liechtenstein

30.6.2012

EU/1/06/335/001

Valtropin

Iceland

5.6.2012

EU/1/06/335/001

Valtropin

Liechtenstein

30.6.2012

EU/1/06/351/001-003

Livensa

Iceland

11.4.2012

EU/1/06/351/001-003

Livensa

Liechtenstein

30.4.2012

EU/1/06/352/001-003

Intrinsa

Liechtenstein

30.6.2012

EU/1/06/352/001-003

Intrinsa

Iceland

23.6.2012

EU/1/09/534/001-007

Clopidogrel Hexal

Iceland

2.3.2012

EU/1/09/534/001-007

Clopidgrel Hexal

Liechtenstein

29.2.2012

EU/1/09/548/001-007

Clopidogrel Acino Pharma GmbH

Iceland

2.3.2012

EU/1/09/548/001-007

Clopidgrel Acino Pharma GmbH

Liechtenstein

29.2.2012

EU/1/09/549/001-007

Clopidogrel Acino Pharma

Iceland

2.3.2012

EU/1/09/549/001-007

Clopidogrel Acino Pharma

Liechtenstein

29.2.2012

EU/1/10/630/001-002

Docefrez

Iceland

20.6.2012

EU/1/10/630/001-002

Docefrez

Liechtenstein

30.6.2012

EU/1/97/035/003-004

Refludan

Iceland

24.5.2012

EU/1/97/035/001-004

Refludan

Norway

6.6.2012

EU/1/97/035/001-004

Refludan

Liechtenstein

30.6.2012

EU/2/00/028/002-008

Zubrin

Iceland

17.4.2012

EU/2/00/028/002-008

Zubrin

Liechtenstein

30.4.2012

EU/2/03/040/001-002

Gonazon

Norway

2.4.2012

EU/2/03/040/001-002

Gonazon

Iceland

17.4.2012

EU/2/03/040/001-002

Gonazon

Liechtenstein

30.4.2012

EU/2/06/060/001-002

Poulvac FluFend H5N3 RG

Liechtenstein

30.6.2012

---

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2012:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/06/361/001-002 | Luminity | Iceland | 20.6.2012 |
| EU/1/06/361/001-002 | Luminity | Liechtenstein | 30.6.2012 |
| EU/1/97/037/001 | Vistide | Liechtenstein | 29.2.2012 |
| EU/1/11/705/001 | Vibativ | Iceland | 27.6.2012 |

EU-Number

Product

Country

Date of authorisation

EU/1/06/361/001-002

Luminity

Iceland

20.6.2012

EU/1/06/361/001-002

Luminity

Liechtenstein

30.6.2012

EU/1/97/037/001

Vistide

Liechtenstein

29.2.2012

EU/1/11/705/001

Vibativ

Iceland

27.6.2012

---